10/27
11:23 am
urgn
Urogen Pharma (NASDAQ:URGN) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $40.00 price target on the stock.
Medium
Report
Urogen Pharma (NASDAQ:URGN) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $40.00 price target on the stock.